[go: up one dir, main page]

CO5271648A1 - Novedosas retinamidas de acido 7-aril-6(z)heptatrienoico - Google Patents

Novedosas retinamidas de acido 7-aril-6(z)heptatrienoico

Info

Publication number
CO5271648A1
CO5271648A1 CO99078060A CO99078060A CO5271648A1 CO 5271648 A1 CO5271648 A1 CO 5271648A1 CO 99078060 A CO99078060 A CO 99078060A CO 99078060 A CO99078060 A CO 99078060A CO 5271648 A1 CO5271648 A1 CO 5271648A1
Authority
CO
Colombia
Prior art keywords
alkyl
hydrogen
retinamids
aril
new
Prior art date
Application number
CO99078060A
Other languages
English (en)
Inventor
Cheung Adrian Wai-Hing
Stephen B Ferguson
Helen Foley
Allen J Lovey
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5271648A1 publication Critical patent/CO5271648A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuesto de fórmula I <EMI FILE="99078060_1" ID="1" IMF=JPEG >En donde R1 y R2 son independientemente entre sí, hidrógeno, halógeno, alquilo, alcoxi o trihalometilo; R3 es hidrógeno o alquilo; y R4 es hidrógeno excepto cuando R3 es alquilo entonces R4 puede ser alquilo; R5 , R6 y R8 y R9 son independientemente entre sí, halógeno, hidrógeno, hidroxilo, alquilo o alquiloxilo: y R7 es hidrógeno o alquilo; los cuales están libres de isómeros 6-trans.
CO99078060A 1998-12-17 1999-12-14 Novedosas retinamidas de acido 7-aril-6(z)heptatrienoico CO5271648A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11263498P 1998-12-17 1998-12-17

Publications (1)

Publication Number Publication Date
CO5271648A1 true CO5271648A1 (es) 2003-04-30

Family

ID=22345016

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99078060A CO5271648A1 (es) 1998-12-17 1999-12-14 Novedosas retinamidas de acido 7-aril-6(z)heptatrienoico

Country Status (20)

Country Link
US (2) US6419952B2 (es)
EP (1) EP1140012B1 (es)
JP (1) JP2002532406A (es)
KR (1) KR100634069B1 (es)
CN (1) CN1161101C (es)
AT (1) ATE260642T1 (es)
AU (1) AU765909C (es)
CA (1) CA2354472C (es)
CO (1) CO5271648A1 (es)
DE (1) DE69915346T2 (es)
DK (1) DK1140012T3 (es)
ES (1) ES2213404T3 (es)
HU (1) HUP0104721A3 (es)
IL (2) IL143691A0 (es)
MX (1) MXPA01006108A (es)
NO (1) NO20012959L (es)
NZ (1) NZ512410A (es)
PT (1) PT1140012E (es)
WO (1) WO2000035419A2 (es)
ZA (1) ZA200104928B (es)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2020229A1 (en) * 1998-11-02 2009-02-04 Elan Pharma International Limited Multiparticulate modified release composition
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
JP2002532406A (ja) * 1998-12-17 2002-10-02 アルザ・コーポレーション 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換
AU2084801A (en) * 1999-12-09 2001-06-18 Alza Corporation Antiviral medication
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
MXPA03012041A (es) * 2001-07-04 2004-03-26 Sun Pharmaceutical Ind Ltd Sistema de administracion controlada de farmacos de retencion gastrica.
US6720002B2 (en) * 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
NZ533060A (en) * 2001-12-19 2006-03-31 Alza Corp Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
IL162294A0 (en) * 2001-12-19 2005-11-20 Alza Corp Formulation & dosage form for the controlled delivery of therapeutic agents
EP1551493B1 (en) * 2002-06-26 2007-10-31 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
US20040058000A1 (en) * 2002-06-28 2004-03-25 Dong Liang C. Controlled release capsule for delivery of liquid formulation
AR040301A1 (es) * 2002-06-28 2005-03-23 Alza Corp Composicion osmotica expansible y suspension para revestimiento mejoradas
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CN1684670A (zh) * 2002-07-29 2005-10-19 阿尔扎公司 用于控制释放帕潘立酮的方法和剂型
USD475451S1 (en) 2002-09-09 2003-06-03 Access Business Group International Llc Vitamin tablet
MXPA05004251A (es) * 2002-10-21 2005-07-05 Givaudan Sa Composiciones pesticidas.
JP2006507309A (ja) * 2002-10-31 2006-03-02 アルザ・コーポレーシヨン 疎水性薬剤の上昇した生物学的利用性を提供する製剤
AR041744A1 (es) * 2002-10-31 2005-05-26 Alza Corp Formas de dosificacion que proporcionan la liberacion ascendente de una formulacion liquida
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
US7037521B2 (en) * 2003-03-28 2006-05-02 Bausch & Lomb Incorporated Using a laser for cutting a hole in a capsule for controlled drug delivery
SI1635787T1 (sl) * 2003-06-26 2012-04-30 Psivida Inc Bioeredibilni sistemi za oddajanje zdravil z zadrževanim sproščanjem
AR044926A1 (es) 2003-06-26 2005-10-12 Control Delivery Sys Inc Sistema de suministro de farmacos gelificante in situ
ATE536861T1 (de) 2003-06-26 2011-12-15 Control Delivery Sys Inc Bioerodierbare arzneimittelabgabesysteme mit verzögerter freisetzung
US20050003070A1 (en) * 2003-07-03 2005-01-06 Foster David V. Shelf stable vitamin C in oatmeal products
MXPA06000363A (es) * 2003-07-11 2006-03-28 Hoffmann La Roche Forma de dosificacion oral de mesilato de saquinavir.
JP5296314B2 (ja) * 2003-07-17 2013-09-25 バナー ファーマキャップス，インコーポレイティド 制御放出製剤
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
KR20060054396A (ko) * 2003-07-31 2006-05-22 알자 코포레이션 액체 활성성분 제제의 방출 제어를 위한 침투-저항 삼투성엔진 및 제형
BRPI0318456B8 (pt) * 2003-08-08 2021-05-25 Biovail Laboratories Int Srl tablete com liberação modificada
USD520635S1 (en) 2003-09-16 2006-05-09 Novartis Ag Combine capsule and tablets
USD530814S1 (en) 2003-09-16 2006-10-24 Novartis Ag Combined capsule and tablets
WO2005030180A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Osmotic dosage forms for controlled delivery of alprazolam
EP1689367A1 (en) * 2003-10-21 2006-08-16 Actavis Group HF Pharmaceutical formulations containing quetiapine
JP2007511519A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 液状投薬形態物におけるトピラメートの制御放出
US20050181049A1 (en) * 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
EP1593376A1 (en) * 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
KR101301429B1 (ko) 2004-11-23 2013-08-30 아다마스 파마슈티칼스, 인코포레이티드 서방성 코팅 또는 매트릭스 및 ｎｍｄａ 수용체 길항제를포함하는 조성물, 대상에 대한 상기 ｎｍｄａ 길항제의투여 방법
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
EP1827377B1 (en) * 2004-12-14 2008-03-19 Novartis AG In-situ forming implant for animals
CA2596029A1 (en) * 2005-01-27 2006-08-03 David E. Edgren Oral osmotic dosage form having a high flux membrane
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DE602006016934D1 (de) 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
CA2624897C (en) * 2005-10-12 2017-02-14 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
US20070208041A1 (en) * 2005-10-13 2007-09-06 Stamler Jonathan S Compositions for the treatment and prevention of heart disease and methods of using same
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8426391B2 (en) 2006-02-03 2013-04-23 Proventiv Therapeutics, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US20070196487A1 (en) * 2006-02-16 2007-08-23 Geerke Johan H Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US20070281008A1 (en) * 2006-06-05 2007-12-06 Lin Shun Y Personal lubricant compositions and kits for providing personal lubrication
SI2679228T1 (en) 2006-06-21 2018-06-29 Opko Ireland Global Holdings, Ltd. THERAPY WITH THE USE OF VITAMIN D ADDITIONAL FIBER AND HORMON RESISTANCE OF VITAMIN D
DE102006032426A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
DE102006032427A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
US20080038334A1 (en) * 2006-08-08 2008-02-14 John Zazula Method for producing and a system for cooling a hot-filled softgel capsule
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
EP2106732B1 (en) * 2007-01-30 2016-03-16 Olympus Corporation Device for checking for lumen passage and method of producing device for checking for lumen passage
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
ES3047207T3 (en) 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US8592401B2 (en) 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
NZ578664A (en) * 2007-06-08 2011-11-25 Boehringer Ingelheim Int Extended release formulation of nevirapine
CN105534936B (zh) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
EP2209455A1 (en) * 2007-10-15 2010-07-28 Glaxo Group Limited Paneled capsule shells for release of pharmaceutical compositions
WO2009050193A1 (en) * 2007-10-15 2009-04-23 Glaxo Group Limited Method and apparatus for manufacturing filled linkers
EP2537506A1 (en) * 2007-10-15 2012-12-26 Capsugel Belgium NV Linkers for multipart dosage forms for release of one or more parmaceutical compositions, and the resulting dosage forms
US20090110724A1 (en) * 2007-10-31 2009-04-30 Everett Laboratories, Inc. Compositions and methods for treatment of pain
EP3320921B1 (en) * 2007-11-05 2022-01-05 Ala Wai Pharma, Inc. Formulations for enhanced bioavailability of orally administered polar agents
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
EP2234963B1 (en) 2007-12-28 2020-04-08 Impax Laboratories, LLC Controlled release formulations of levodopa and uses thereof
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
CA2714996C (en) 2008-04-02 2020-04-07 Cytochroma Inc. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
AU2010234343A1 (en) * 2009-04-09 2011-11-24 Alkermes Pharma Ireland Limited Controlled-release clozapine compositions
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2011006066A1 (en) 2009-07-10 2011-01-13 Ironwood Pharmaceuticals, Inc. Cb receptor agonists
CN101596174B (zh) * 2009-07-13 2011-04-06 北京航洋胶囊技术有限公司 一种软胶囊及其制备方法
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
CA2776173A1 (en) 2009-09-30 2011-04-07 Nicholas Marini Cofactors and methods of use for individuals
CA2777856A1 (en) 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
WO2011079007A1 (en) 2009-12-23 2011-06-30 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2011100324A1 (en) 2010-02-09 2011-08-18 Ironwood Pharmaceuticals Inc. Cannabinoid receptor agonists
WO2011100359A1 (en) 2010-02-09 2011-08-18 Ironwood Pharmaceuticals, Inc. Cannabinoid agonists
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US8486013B2 (en) * 2010-03-18 2013-07-16 Biotronik Ag Balloon catheter having coating
RS60087B1 (sr) 2010-03-29 2020-05-29 Opko Ireland Global Holdings Ltd Postupci i kompozicije za snižavanje nivoa paratireoidnog hormona
CN103209704B (zh) * 2010-04-22 2017-10-27 细胞内治疗公司 有机化合物
WO2011161666A2 (en) * 2010-06-21 2011-12-29 White Innovation Ltd. Enclosed liquid capsules
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
RU2582679C2 (ru) 2010-11-09 2016-04-27 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103889411B (zh) 2011-07-15 2018-03-16 纽斯尔特科学公司 用于调节代谢途径的组合物和方法
TWI615155B (zh) * 2011-11-01 2018-02-21 拜耳股份有限公司 滲透活性的陰道遞送系統
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
CN103211797B (zh) * 2012-01-18 2017-06-06 北京天衡医院管理有限公司 盐酸维拉帕米膜控缓释微丸胶囊
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
WO2013155422A1 (en) 2012-04-12 2013-10-17 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
CA2870303A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Organic compounds
BR112014026614A2 (pt) * 2012-04-30 2017-06-27 Dow Agrosciences Llc veículos de administração de composições pesticidas
WO2014017756A1 (ko) * 2012-07-23 2014-01-30 삼성정밀화학(주) 경질 캡슐 제조용 수성 조성물, 그의 제조방법, 경질 캡슐 및 경질 캡슐 스크랩의 재활용 방법
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
CN105101958B (zh) 2013-01-15 2019-05-17 纽斯尔特科学公司 治疗肺病状
GB201303781D0 (en) 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
HUE053159T2 (hu) * 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek
AU2014236687A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
LT3660013T (lt) 2013-03-15 2022-04-11 Cyclerion Therapeutics, Inc. Tgs stimuliatoriai
CN103315973B (zh) * 2013-05-24 2014-05-07 杭州和正医药有限公司 喹硫平的渗透泵型控释制剂
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP2839853A1 (de) * 2013-08-23 2015-02-25 LTS LOHMANN Therapie-Systeme AG Transdermales therapeutisches System mit Druckerzeugungsvorrichtung
MX393588B (es) 2013-10-07 2025-03-04 Impax Laboratories Llc Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
IL246002B2 (en) 2013-12-03 2024-11-01 Intra Cellular Therapies Inc Converted compounds of gamma-carboline fused with heterocycles for use in the treatment of residual symptoms of psychosis and a long-acting injectable preparation containing these compounds in a matrix
MX2016007522A (es) 2013-12-11 2017-12-15 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
KR102161001B1 (ko) * 2013-12-31 2020-09-29 롯데정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
KR102199596B1 (ko) * 2013-12-31 2021-01-07 롯데정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
WO2015131152A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
JP2017509677A (ja) 2014-04-04 2017-04-06 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US9808608B2 (en) * 2014-11-16 2017-11-07 International Business Machines Corporation Helical coil delivery device for active agent
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
US20170119680A1 (en) 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
MX2018008021A (es) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
IL318649A (en) 2016-01-26 2025-03-01 Intra Cellular Therapies Inc Organic compounds
BR112018069594B1 (pt) 2016-03-25 2023-12-05 Intra-Cellular Therapies, Inc Compostos orgânicos, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de um distúrbio do sistema nervoso central
SG11201808227YA (en) 2016-03-28 2018-10-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2017292791B2 (en) * 2016-07-06 2023-05-25 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
WO2018045276A1 (en) 2016-09-02 2018-03-08 Ironwood Pharmaceuticals, Inc. Fused bicyclic sgc stimulators
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
MA46752A (fr) 2016-11-08 2019-09-18 Cyclerion Therapeutics Inc Traitement de maladies du snc au moyen de stimulateurs de gcs
IL266372B2 (en) 2016-11-08 2023-11-01 Cyclerion Therapeutics Inc Running SGC
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
MX2020000968A (es) 2017-07-26 2020-09-28 Intra Cellular Therapies Inc Compuestos organicos.
IL272252B2 (en) 2017-07-26 2024-03-01 Intra Cellular Therapies Inc Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment
EP3765021A4 (en) 2018-03-16 2022-03-09 Intra-Cellular Therapies, Inc. NOVEL PROCESSES
WO2019183546A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
WO2019183341A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
WO2019204187A1 (en) * 2018-04-15 2019-10-24 Optofluidic Bioassay, Llc Differential pressure assisted drainage system
MX2020013335A (es) 2018-06-08 2021-05-27 Intra Cellular Therapies Inc Metodos novedosos.
CA3240552A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
MX2021002322A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
US12195462B2 (en) 2018-12-17 2025-01-14 Intra-Cellular Therapies, Inc. Organic compound
MX2022000143A (es) 2019-07-07 2022-02-17 Intra Cellular Therapies Inc Metodos novedosos.
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC COMPOUND
US10940088B1 (en) * 2020-01-09 2021-03-09 King Saud University Method of preparing low dose pharmaceutical formulations
CN112641751B (zh) * 2020-09-25 2022-06-21 广州玖洲胶囊生物科技有限公司 一种羟丙甲基纤维素和卡拉胶的填充空心充液胶囊
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
JP2026502895A (ja) 2022-12-30 2026-01-27 イントラ－セルラー・セラピーズ・インコーポレイテッド セロトニン５－ｈｔ２ａ受容体に作用する複素環縮合ガンマ－カルボリン
CN116650438A (zh) * 2023-06-26 2023-08-29 江苏理工学院 一种软胶囊囊壳、可实现快速移动的软胶囊及制备方法
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor
WO2026011136A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
AU591171B2 (en) * 1983-11-02 1989-11-30 Alza Corporation Dispenser for delivering thermo-responsive composition
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
PT100944B (pt) * 1991-10-10 2000-02-29 Alza Corp Dispositivo para o fornecimento osmotico de farmacos com paredes de materiais hidrofobicos
DE69431533T2 (de) * 1994-06-13 2003-10-02 Alza Corp., Palo Alto Dosierungsform zur verabreichung von flüssige arzneimittel formulierung
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5800422A (en) * 1995-06-02 1998-09-01 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
IT1289160B1 (it) 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
JP2002532406A (ja) * 1998-12-17 2002-10-02 アルザ・コーポレーション 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換

Also Published As

Publication number Publication date
US20010036472A1 (en) 2001-11-01
IL143691A0 (en) 2002-04-21
KR100634069B1 (ko) 2006-10-16
NZ512410A (en) 2003-02-28
HUP0104721A2 (en) 2002-06-29
US20020155154A1 (en) 2002-10-24
MXPA01006108A (es) 2002-09-18
NO20012959D0 (no) 2001-06-15
WO2000035419A2 (en) 2000-06-22
AU765909C (en) 2004-09-23
WO2000035419A3 (en) 2000-11-09
CA2354472C (en) 2009-02-24
AU765909B2 (en) 2003-10-02
NO20012959L (no) 2001-08-10
ATE260642T1 (de) 2004-03-15
HK1040632A1 (en) 2002-06-21
AU2199400A (en) 2000-07-03
HUP0104721A3 (en) 2006-07-28
DK1140012T3 (da) 2004-07-12
IL143691A (en) 2009-02-11
ES2213404T3 (es) 2004-08-16
CN1161101C (zh) 2004-08-11
DE69915346T2 (de) 2004-07-22
ZA200104928B (en) 2002-06-18
CA2354472A1 (en) 2000-06-22
US6419952B2 (en) 2002-07-16
EP1140012B1 (en) 2004-03-03
JP2002532406A (ja) 2002-10-02
EP1140012A2 (en) 2001-10-10
US6929803B2 (en) 2005-08-16
DE69915346D1 (de) 2004-04-08
PT1140012E (pt) 2004-05-31
CN1331580A (zh) 2002-01-16
KR20010087422A (ko) 2001-09-15

Similar Documents

Publication Publication Date Title
CO5271648A1 (es) Novedosas retinamidas de acido 7-aril-6(z)heptatrienoico
ATE245636T1 (de) Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
NO20015226D0 (no) Tri-aryl syrederivater som PPAR reseptor ligander
CO5150176A1 (es) Antagonistas iii del receptor ccr-3 de los receptores ccr-3 composicio farmaceutica que los con- tiene y procedimiento para la preparacion de estos compues- tos.
IL154272A (en) Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
KR880009910A (ko) 리폭시게네이즈 억제 화합물
ES2160408T3 (es) Trifluorfenil-triazolpirimidinas fungicidas.
AR247213A1 (es) Preparacion de acido 7-¡(1-carboxi-3-fenilpropil)amino¿-3,4,6,7,8,12b-octahidro-6-oxopirido ¡2,1-a¿ o hexahidro-6-oxo-1h(1,4-tiazino¡3,4-a¿¡2¿-benzazepin-4-carboxilico, agentes hipertensivos.
ES523191A0 (es) Procedimiento para la preparacion de 1-ariloxi-2,3,4,5-tetrahidro-3-benzazepinas
CO5190683A1 (es) Analogos de vitamina d3
EA199800987A1 (ru) Бензоксазиноновые антагонисты рецептора допамина d4
ES8207553A1 (es) Un procedimiento para la preparacion de dipeptidil-4-0,60-2-amino-2-desoxi-d-glucosa.
AR006189A1 (es) Aminoalquil-eteres y acilaminoalquil-eteres, procedimiento para su preparacion y su utilizacion como antagonistas de receptores de bradiquinina
CO5200762A1 (es) Preparacion de piperidin-4-onas sustituidas
DE59908967D1 (de) Indolinderivate als lichtschutzmittel
YU44301A (sh) 5ht1 antagonisti za antidepresantnu terapiju
CO4930273A1 (es) Derivados de 5-aroilnaftaleno
EA199600007A2 (ru) Новые трициклические производные, способ их получения, способы получения оптически активных или рацемических колхицина и тиоколхицина, их аналогов или производных с использованием трициклических соединений и промежуточные продукты синтеза
CO5210860A1 (es) Nuevos derivados de pirimidina-2,4,6-triona
UY25861A1 (es) Retinamidas del acido 7-aril-6-(z) heptatrienico
CA2022451A1 (en) Anti-psychotic piperidynl benzimidazole compounds
ES2038159T3 (es) Procedimiento para preparar derivados sustituidos de 2-aminoacetamida.
NO890158D0 (no) Fremgangsmaate for fremstilling av hydroksialkyleringsmiddel, de oppnaadde midler og deres anvendelse.
PA8524001A1 (es) Proceso para preparar 2-(4-piridil)amino-6-dialquiloxifenil-pirido (2,3-d) pirimidin-7-onas
MY102276A (en) Antimykotische aminoazole i

Legal Events

Date Code Title Description
FA Application withdrawn